STEWARTVILLE, Minn., May 5, 2011 /PRNewswire/ -- Rochester Medical Corporation (NASDAQ: ROCM) today announced operating results for its second quarter ended March 31, 2011.
The Company reported record sales of $12,853,000 for the current quarter compared to $9,845,000 for the second quarter of last year. It also reported net loss of ($1,259,000) or ($0.10) per diluted share compared to net loss of ($351,000) or ($0.03) per diluted share for the same quarter of last year.
The approximate 31% increase in sales (29% on constant currency basis) resulted from a 39% increase in Rochester Medical Direct Sales (37% on a constant currency basis) and an 8% increase in Private Label Sales (8% on a constant currency basis). Direct Sales include sales made directly to the end consumer and include all Rochester Medical branded sales, UK Script Easy sales, and all Laprolan sales. Beginning with the second quarter of this fiscal year, the Company's operating results include the operating results of Laprolan B.V., the Company's newly acquired subsidiary in The Netherlands. Constant currency basis assumes current exchange rates for all periods in order to exclude the impact of foreign exchange variations. In the second quarter of fiscal 2011, the U.S. dollar was somewhat weaker versus the pound sterling thus positively affecting Rochester Medical Direct Sales growth levels in actual U.S. dollars given the significant volume of direct sales in the United Kingdom.
Net loss adjusted for certain non-recurring unusual items and certain recurring non-cash expenses, or "Non-GAAP Net Income (Loss)" for the current quarter was ($437,000) or ($.04) per diluted share compared to Non-GAAP Net Income of $140,000 or $.01 per diluted share for the second quarter of last year. The net loss for the current quarter is attributable to the recent significant increase in the Company's strategic investment in Sales and Marketing. In the second quarter the completed expansion of the U.S. sales and marketing force added over a million dollars in incremental costs compared to the same period last year. The Company believes the investment will generate significant increases in revenue over the next few years.
Commenting on today's results Rochester Medical's CEO and President Anthony J. Conway said, "The excellent 37% constant currency growth in Direct Sales for the quarter was in large part due to the Laprolan acquisition reinforced by continued solid growth in Direct Sales of 24% in the combined U.S. and U.K. markets where we have a sales force presence. The growth was partially offset by a decline in Direct Sales in other parts of the world due to timing of orders and shipments.
"I want to thank our Laprolan employees for their spirit of co-operation and excitement as they have become an important part of the Rochester Medical Team. Now, with significant presence in the U.K., The Netherlands, and the United States, and with sales in countries throughout the world, we are truly becoming a recognized global leader in our field."
Conway concluded, "By fiscal year end we expect to be operating profitably. Looking ahead, we are strongly focused on growing the top line, flattening costs, and generating profits."
Acquisition of Laprolan B.V.On April 7, 2011, Rochester Medical announced the completed acquisition of Laprolan B.V., the former Medical Supplies Division and wholly owned subsidiary of Fornix BioSciences N.V. Under the terms of the purchase agreement the purchase is deemed retroactive to January 1, 2011. The final purchase price for Laprolan B.V., was $14,878,125 net of interest paid.
Agreement with Teleflex IncorporatedRochester Medical today announced an exclusive agreement with Teleflex Incorporated whereby they will market and sell Rochester Medical's Strata-NF Anti-Infection Foley Catheter in a number of countries in mainland Europe.
Conference Call and WebcastThe Company will hold a quarterly conference call today to discuss its earnings report. The call will begin at 3:30 p.m. central time (4:30 p.m. eastern time).
This call is being webcast by Thomson/CCBN and can be accessed at Rochester Medical's website at www.rocm.com. To listen live to the conference call via telephone, call:Domestic:
65580251Pre Registration: https://www.theconferencingservice.com/prereg/key.process?key=P6YE3FJK6Replay will be available for seven days at www.rocm.com or via telephone at:Domestic:
70081655Individual investors can listen to the call at www.fulldisclosure.com, Thomson/CCBN's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents (www.streetevents.com).
Use of Non-GAAP Financial MeasuresRochester Medical has provided Non-GAAP Net Income (Loss) in addition to net income (loss) calculated in accordance with generally accepted accounting principles (GAAP) because management believes Non-GAAP Net Income (Loss) provides a more consistent basis for comparisons that are not influenced by certain charges and non-cash expenses and are therefore helpful in understanding Rochester Medical's underlying operating results. Similarly, constant currency represents reported sales with the cost/benefit of currency movements removed. Management uses the measure to understand the growth of the business on a constant dollar basis, as fluctuations in exchange rates can distort the underlying growth of the business both positively and negatively. While we recognize that foreign exchange volatility is a reality for a global company, we routinely review our Company performance on a constant dollar basis, and we believe this also allows our shareholders to understand better our Company's growth trends.
Non-GAAP Net Income (Loss) and constant currency are not measures of financial performance under GAAP, and should not be considered an alternative to net income or any other measure of performance or liquidity under GAAP. Non-GAAP Net Income (Loss) and constant currency are not comparable to information provided by other companies. Non-GAAP Net Income (Loss) and constant currency have limitations as analytical tools and should not be considered in isolation or as a substitution for analysis of our results as reported under GAAP. Reconciliations of Net Loss and Non-GAAP Net Income (Loss), and reconciliations of sales under GAAP and sales on a constant currency basis, are presented at the end of this press release.
About Rochester Medical CorporationRochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications. The Company also sells certain ostomy and wound and scar care products and other brands of urological products into the European marketplace.
For further information, please contact Anthony J. Conway, President and Chief Executive Officer or David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600 or Parice Halbert, CFA, at Westwicke Partners (443) 213-0500. More information about Rochester Medical is available on its website at http://www.rocm.com.
Forward-Looking StatementsThis press release contains "forward-looking statements" with the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the future financial and operating results of Rochester Medical. Such statements are based on currently available information, operating plans and management's expectations about future events and trends. Such statements inherently involve significant risks and uncertainties that could cause actual results to differ materially from those predicted in such forward-looking statements, including the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the uncertainty of market acceptance of new product introductions and our level of success in increasing Rochester Medical Direct Sales revenue, the uncertainty of gaining new strategic relationships or locating and capitalizing on strategic opportunities, the uncertainty of timing of Private Label Sales revenues (particularly international customers), FDA and other regulatory review and response times, and other risk factors listed from time to time in the Company's SEC reports and filings, including, without limitation, the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended September 30, 2010, and reports on Forms 10-Q and 8-K. Readers are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Rochester Medical CorporationPress Release - F11 Second Quarter Summary Statements Of Operations (unaudited)(unaudited)Three months endedSix months endedMarch 31,March 31,2011201020112010Sales
$ 12,852,601$ 9,845,480$ 23,799,006$ 20,077,292Cost of sales
6,359,1944,659,08411,763,3259,272,192Gross profit %
49.5%47.3%49.4%46.2%Costs and expenses:Marketing and selling
5,012,7472,871,6758,894,7275,648,992Research and development
251,672241,390529,527684,418General and administrative
2,403,6981,747,6044,112,7913,438,351Total operating expenses
7,668,1174,860,66913,537,0459,771,761Loss from operations
(1,308,923)(201,585)(1,773,720)(499,569)Other income (expense)Interest income
(12,865)(34,739)(29,147)(61,386)Net loss before income taxes
(1,393,407)(226,077)(1,853,175)(536,170)Income tax expense(benefit)
$ (1,259,398)$ (351,416)$ (1,428,480)$
(520,574)Loss per common share - Basic
(0.04)Loss per common share - Diluted
(0.04)Weighted Average Shares:
12,223,34712,195,33412,174,78012,193,441BasicWeighted Average Shares:Diluted
12,223,34712,195,33412,174,78012,193,441Rochester Medical CorporationPress Release - F11 Second Quarter Condensed Balance Sheets(unaudited)March 31,September 30,20112010Current AssetsCash and equivalents
11,867,1399,240,291Prepaid expenses and other assets
2,236,128846,899Deferred income tax
851,562872,849Total current assets
58,492,71254,331,493Property and equipment, net
11,929,96710,017,239Deferred income tax
1,195,4401,175,052Intangible assets, net
$ 93,458,579$ 75,666,291Current liabilities:Accounts payable
16,723,9982,641,233Total current liabilities
69,847,85668,893,451Total Liabilities and Stockholder's Equity
$ 93,458,579$ 75,666,291ROCHESTER MEDICAL CORPORATIONReconciliation of Reported GAAP Revenue to Non-GAAP Revenue in Constant CurrencyFor the Three and Six months endedMarch 31, 2011(unaudited)(unaudited)Three months endedSix months endedMarch 31,March 31,2011
2010GAAP Sales as Reported
20,077,292Exchange rate as Reported
1.60Constant Currency Sales
20,056,899 (1) Exchange rate used for Constant Currency Purposes
1.59Net Effect of Constant Currency Illustration
(20,393)(1) For illustrative purposes Constant currency translates prior period foreign sales at current exchange rates.
For Rochester Medical Corporation this is the conversion rate of British pounds to US dollars and the Euro to US Dollars. The rate represents the average exchange rate for the respective three or six month period. For fiscal 2011 there will be no rate variance from the Euro to the US dollar.ROCHESTER MEDICAL CORPORATIONReconciliation of Reported GAAP Net (Loss) to Non-GAAP Net Income (Loss)For the Three and Six months endedMarch 31, 2011 and 2010(unaudited)(unaudited)Three months endedSix months endedMarch 31,March 31,2011
2010GAAP Net Income (Loss) as Reported
$ (351,000)$ (1,428,000)
$ (521,000)Diluted EPS as Reported
(0.04)Adjustments for non-recurring unusual items: Merger and acquisition costs for Laprolan (1)
-Adjustments for recurring non-cash expenses: Intangible amortization (2)
258,000 ASC 718 compensation expense (3)
808,000Non-GAAP Net Income (Loss)
287,000Non-GAAP Diluted EPS
.02Weighted Average Shares - Diluted
12,703,486(1) Merger and acquisition costs related to the purchase of Laprolan B.V. from Fornix N.V.(2) Amortization of the intangibles acquired in June 2006 asset acquisition from Coloplast AS and Mentor Corporation and the intangibles acquired in the January 2011 acquisition of Laprolan from Fornix N.V. Management believes these assets are appreciating. This adjustment adds back amortization expense for the three and sixth months ended March 31, 2011 and 2010 related to certain intangibles. The gross amount of amortization expense for the three months ended March 31, 2011 and 2010 is $251,000 and $163,000 net of taxes of $56,000 and $34,000 for net amounts of $195,000 and $129,000 respectively. The gross amount of amortization expense for the six months ended March 31, 2011 and 2010 is $414,000 and $326,000 net of taxes of $91,000 and $68,000 for net amounts of $323,000 and $258,000 respectively.(3) Compensation expense mandated by ASC 718. This adjustment adds back the compensation expense recorded for stock options granted to employees and directors that vested during the three and sixth months ended March 31, 2011 and 2010. The gross amount of compensation expense for the three months ended March 31, 2011 and 2010 is $582,000 and $565,000 net of taxes of $210,000 and $203,000 for net amounts of $372,000 and $362,000 respectively. The gross amount of compensation expense for the six months ended March 31, 2011 and 2010 is $877,000 and $850,000 net of taxes of $310,000 and $300,000 for net amounts of $567,000 and $550,000 respectively.
|SOURCE Rochester Medical Corporation|
Copyright©2010 PR Newswire.
All rights reserved